Biotech Values

[DewDiligence]

The control treatment in PARS’ pump-head trial is indeed a placebo:

http://www.pharmoscorp.com/news/pr/pr040803.html
>>
Patients are being randomized one-to-one to receive a single dose of either 150 mg. dexanabinol or placebo prior to initiation of CPB. Each patient will be evaluated prior to surgery, at discharge, at six weeks, and at three months following surgery to assess the incidence and degree of post-surgical CI. The degree of cognitive impairment will be assessed using a sophisticated and validated battery of computerized neuropsychological tests including attention deficit, memory loss and speed of reaction.
<<